Drug data last refreshed 3h ago · AI intelligence enriched 4d ago
Thioguanine is an oral small-molecule purine analog approved in 1966 for hematologic malignancies and autoimmune conditions. It functions as a prodrug that is converted intracellularly to active nucleotides, disrupting nucleic acid synthesis in rapidly dividing cells. The drug is primarily used in leukemia and inflammatory bowel disease management.
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely transitioning from growth management to defensive positioning and cost optimization.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on thioguanine offers limited growth opportunity but valuable exposure to lifecycle management, generic defense strategies, and mature-market brand optimization at Viatris. Positions on this product are best suited for professionals interested in operational efficiency, managed-care negotiation, and post-LOE brand stewardship rather than launch excitement or clinical innovation.
Worked on THIOGUANINE at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.